The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
N‐acetylcysteine showed no clear difference in participants abstinent at end of treatment compared with placebo (low certainty).
N‐acetylcysteine showed no clear difference in participants experiencing adverse effects compared with placebo (moderate certainty).
N‐acetylcysteine showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).
N‐acetylcysteine showed no clear difference in completion of scheduled treatment compared with placebo (moderate certainty).
It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes eradication rate compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).
It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes gastrointestinal adverse events compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).
It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes allergic adverse events compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).
N‐acetylcysteine (1200 mg) showed no clear difference in frequency of crisis (number of pain days) compared with placebo (low certainty).
N‐acetylcysteine (1200 mg) showed no clear difference in severity of pain (maximum pain intensity on pain days) compared with placebo (low certainty).
It is very uncertain whether N‐acetylcysteine (1200 mg) changes qoL of participants living with SCD and their caregivers (measured… compared with placebo (very low certainty).
N‐acetylcysteine (1200 mg) showed no clear difference in adverse effects compared with placebo (low certainty).
N‐acetylcysteine (1200 mg) may leads to lower frequency of hospitalization compared with placebo (low certainty).
It is very uncertain whether N‐acetylcysteine (1200 mg) changes frequency of sickle cell‐related complications (acute chest syndrome) compared with placebo (very low certainty).
N‐acetylcysteine (1200 mg) showed no clear difference in haemoglobin status compared with placebo (low certainty).
It is very uncertain whether the intervention changes clinical pregnancy; type of antioxidant (natural conceptions and… (very low certainty).
The intervention showed no clear difference in mortality 30‐day (moderate certainty).